Novartis (NYSE:NVS) Upgraded by StockNews.com to Strong-Buy Rating
Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...
BioPharma Dive10h
Pfizer taps former Novartis exec to lead cancer drug push
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation ...